Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs (CLI): Study of the Needs of Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 and ≤ 85 years~2. Diabetic type 2, in treatment with insulin at least 3 previous months.~3. Vascular disease infrapopliteal atherosclerotic of severe degree (Patients with category Rutherford-Becker ≥ 4), pretty or bilateral. The critical ischemia of the foot is defined as a persistent / persistent pain that needs analgesia and / or not healing present sores\> 4 weeks, without evidence of improvement with conventional therapies and / or walking test between 1-6 minutes in two ergometries separated at least for 2 weeks and / or index ankle - arm in rest \<0,8.~4. Impossibility of revascularization surgical or endovascular or I fail in the surgery of revascularization performed at least 30 days before, with persistence or entry in phase of critical ischemia~5. Life expectancy \> 2 years.~6. Major amputation is not foreseen in any of the members in the next 6 months after the incorporation.~7. Normal Biochemical and bone marrow parameters defined for:~   * Leukocytes ≥ 3000~  * Neutrophils ≥ 1500~  * Platelets ≥ 140000~  * AST/ALT ≤ 2,5 standard range institution~  * Creatinine ≤2,5 mg/dl and explanation of creatinine ≤ 30 ml/min (MDRD4)~8. The women in fertile age will have to obtain negative results in a pregnancy test realized in the moment of the incorporation in the study and promise to use a contraceptive method medically approved while the study lasts.~9. Patients who give his Informed Consent in writing for the participation in the study. 10. Patients who have not taken part in another clinical trial in the last 3 months before the incorporation.~Exclusion Criteria:~1. Precedent of neoplasia or hematologic disease (disease myeloproliferative, syndrome myelodysplasic or leukaemia) in the last 2 years.~2. Major previous amputation.~3. Patients with arterial uncontrolled hypertension (defined as arterial tension\> 180/110 in more than one occasion).~4. Cardiac severe insufficiency (NYHA the IVth) or Fraction of Ejection of left ventricle (FAITH) lower than 30 %.~5. Patients with ventricular malignant arrhythmias or unstable angina.~6. Diagnosis of venous deep thrombosis in 3 previous months.~7. Patients with genotype DD of the ECA or genotype E4 of the apo E.~8. Concomitant therapy that includes oxygen hyperbaric, vasoactive substances, agents against angiogenesis or inhibiting Cox-II. The agents use is allowed antiplatelets.~9. Index of corporal mass\> 40 Kg/m2.~10. Patients with the diagnosis of alcoholism in the moment of the incorporation.~11. Proliferative Retinopathy without possibility of treatment.~12. Diabetic Nephropathy with haemodialysis~13. Concomitant disease that reduces the life expectancy to less than 1 years.~14. Impossibility foreseen to obtain the inhaled one of 100ml of bone marrow.~15. Infection for HIV, Hepatitis B or Hepatitis C.~16. Impede in the follow-up.~17. ACV or heart attack of myocardium in the last 3 months~18. Anaemia (Haemoglobin \<7.9 g/dl)~19. Patients before treated with cellular therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Autologous mononuclear stem cell from the bone marrow (Type: EXPERIMENTAL): Autologous mononuclear stem cell from the bone marrow in an unique infusion of 150-250 millions of cells
- Autologous endothelial stem cell from the bone marrow (Type: EXPERIMENTAL): Autologous endothelial progenitor CD133 stem cell from the bone marrow in an unique infusion of 2 - 7 millions of CD133 cells
- Autologous mesenchymal stem cells from the adiposite tissue (Type: EXPERIMENTAL): Autologous mesenchymal stem cells from the adipose tissue in an unique infusion of 0.5 millions of cells
- Current medication for the disease (Type: ACTIVE_COMPARATOR): Current medication for the disease

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility